000 03887nam a22004935i 4500
001 978-1-4419-6306-2
003 DE-He213
005 20160615111647.0
007 cr nn 008mamaa
008 110110s2010 xxu| s |||| 0|eng d
020 _a9781441963062
_9978-1-4419-6306-2
024 7 _a10.1007/978-1-4419-6306-2
_2doi
049 _aAlfaisal Main Library
050 4 _aR-RZ
072 7 _aMBGR
_2bicssc
072 7 _aMED000000
_2bisacsh
082 0 4 _a610
_223
245 1 0 _aChemo Fog
_h[electronic resource] :
_bCancer Chemotherapy-Related Cognitive Impairment /
_cedited by Robert B. Raffa, Ronald J. Tallarida.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2010.
300 _aXXI, 216 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v678
505 0 _aShort Introduction and History -- Patient’s Perspective -- Oncology Nurse’s Perspective -- Oncology Pharmacist’s Perspective -- The Impact of Chemo Brain on the Patient with a High-Grade Glioma -- Neurocognitive Effects of Childhood Cancer Treatment -- The Economic Burden -- Designing Conceptual Model-Based Research in Chemotherapy-Related Changes in Cognitive Function -- Neuropsychologic Testing for Chemotherapy-Related Cognitive Impairment -- Imaging as a Means of Studying Chemotherapy-Related Cognitive Impairment -- Chemotherapy Associated Central Nervous System Damage -- Is Systemic Anti-Cancer Therapy Neurotoxic? Does Chemo Brain Exist? And Should We Rename It? -- Evaluation of Multiple Neurotoxic Outcomes in Cancer Chemotherapy -- Chemotherapy-Related Visual System Toxicity -- The Possible Role of Cytokines in Chemotherapy-Induced Cognitive Deficits -- Pharmacokinetics of Anti-Cancer Drugs Used in Breast Cancer Chemotherapy -- Combination Analysis -- Animal Models -- Chemo Brain (Chemo Fog) as a Potential Side Effect of Doxorubicin Administration: Role of Cytokine-Induced, Oxidative/Nitrosative Stress in Cognitive Dysfunction -- Effects of 5-FU -- Future Directions.
520 _aCancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. Due to the advances in chemotherapy and other aspects of prevention, early detection, and treatment modalities, an increasing percentage of patients are surviving the disease. For some types of cancer, the majority of patients live decades beyond their diagnosis. For this they are forever thankful and appreciative of the drugs that helped lead to this increased survival rate. But no drug is devoid of adverse effects. This also applies to chemotherapeutic agents. The acute cytotoxic effects of these agents are well known––indeed are often required for their therapeutic benefit. The chronic adverse effects are varied and in some cases less well known. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects.
650 0 _aMedicine.
650 0 _aCancer research.
650 1 4 _aBiomedicine.
650 2 4 _aBiomedicine general.
650 2 4 _aCancer Research.
655 7 _aElectronic books.
_2local
700 1 _aRaffa, Robert B.
_eeditor.
700 1 _aTallarida, Ronald J.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781441963055
830 0 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v678
856 4 0 _uhttp://ezproxy.alfaisal.edu/login?url=http://dx.doi.org/10.1007/978-1-4419-6306-2
912 _aZDB-2-SBL
942 _2lcc
_cEBOOKS
999 _c291908
_d291908